ProCE Banner Activity

BENEFIT/IFM 2020-05: Phase III Trial of Isa-VRd vs Isa-Rd in Patients With Transplant-Ineligible NDMM

Conference Coverage
Slideset

Current analysis of phase III BENEFIT trial resulted in statistically significant improvement in 18-month MRD-negativity rate with Isa-VRd with weekly bortezomib vs Isa-Rd in patients with transplant-ineligible newly diagnosed multiple myeloma.

Released: June 07, 2024

Expiration: June 06, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from GSK, Lilly, Novartis Pharmaceuticals Corporation, and Sanofi.

GSK

Lilly

Novartis Pharmaceuticals Corporation

Sanofi